Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development, CPT: Pharmacometrics & Systems Pharmacology, vol.32, issue.9, p.6, 2012. ,
DOI : 10.1007/s10928-005-0062-y
Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development???Part 2: Introduction to Pharmacokinetic Modeling Methods, CPT: Pharmacometrics & Systems Pharmacology, vol.14, issue.4, p.38, 2013. ,
DOI : 10.1177/0091270010376965
Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development???Part 2: Introduction to Pharmacokinetic Modeling Methods, CPT: Pharmacometrics & Systems Pharmacology, vol.14, issue.4, p.88, 2014. ,
DOI : 10.1177/0091270010376965
Optimal Sampling Times for a Drug and its Metabolite using SIMCYP?? Simulations as Prior Information, Clinical Pharmacokinetics, vol.39, issue.1, pp.43-57, 2013. ,
DOI : 10.1007/s10928-012-9241-9
URL : https://hal.archives-ouvertes.fr/inserm-00769804
A limited sampling strategy based on maximum a posteriori Bayesian estimation for a five-probe phenotyping cocktail, European Journal of Clinical Pharmacology, vol.2, issue.1, p.39, 2016. ,
DOI : 10.1038/psp.2013.19
Ebola virus dynamics in mice treated with favipiravir, Antiviral Research, vol.123, pp.70-77, 2015. ,
DOI : 10.1016/j.antiviral.2015.08.015
URL : https://hal.archives-ouvertes.fr/inserm-01196078
Mathematical Modeling of Bacterial Kinetics to Predict the Impact of Antibiotic Colonic Exposure and Treatment Duration on the Amount of Resistant Enterobacteria Excreted, PLoS Computational Biology, vol.25, issue.5, pp.1003-840, 2014. ,
DOI : 10.1371/journal.pcbi.1003840.s007
Model-based dose finding under model uncertainty using general parametric models, Statistics in Medicine, vol.44, issue.7, pp.1646-1661, 2014. ,
DOI : 10.1002/1521-4036(200201)44:1<101::AID-BIMJ101>3.0.CO;2-H
URL : http://arxiv.org/pdf/1305.0889
CPT: Pharmacometrics and Systems Pharmacology. CPT: Pharmacometrics & Systems Pharmacology, p.8, 2012. ,
Non-Linear Mixed Effects Modeling ??? From Methodology and Software Development to Driving Implementation in Drug Development Science, Journal of Pharmacokinetics and Pharmacodynamics, vol.72, issue.6, pp.161-183, 2005. ,
DOI : 10.1038/clpt.1994.142
Design of Experiments in Nonlinear Models ,
DOI : 10.1007/978-1-4614-6363-4
URL : https://hal.archives-ouvertes.fr/hal-00879984
Optimal Design for Nonlinear Response Models, 2014. ,
Optimal design in random-effects regression models, Biometrika, vol.84, issue.2, pp.429-442, 1997. ,
DOI : 10.1093/biomet/84.2.429
Simultaneous population optimal design for pharmacokineticpharmacodynamic experiments, American Association of Pharmaceutical Scientists Journal, vol.7, pp.759-785, 2005. ,
DOI : 10.1208/aapsj070476
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750948/pdf
Fisher information matrix for nonlinear mixed effects multiple response models: Evaluation of the appropriateness of the first order linearization using a pharmacokinetic/pharmacodynamic model, Statistics in Medicine, vol.60, issue.14, pp.1940-1956, 2009. ,
DOI : 10.1111/j.0006-341X.2004.00148.x
URL : https://hal.archives-ouvertes.fr/inserm-00371363
Some Considerations on the Fisher Information in Nonlinear Mixed Effects Models, Proceedings of the 9th International Workshop in Model-Oriented Design and Analysis, 2010. ,
DOI : 10.1007/978-3-7908-2410-0_17
Methods and software tools for design evaluation in population pharmacokinetics-pharmacodynamics studies, British Journal of Clinical Pharmacology, vol.282, issue.1, pp.6-17, 2014. ,
DOI : 10.1126/science.282.5386.103
URL : https://hal.archives-ouvertes.fr/inserm-00978789
Design evaluation and optimisation in crossover pharmacokinetic studies analysed by nonlinear mixed effects models, Statistics in Medicine, vol.30, issue.11-12, pp.11-121043, 2012. ,
DOI : 10.1002/sim.4191
URL : https://hal.archives-ouvertes.fr/inserm-00629594
Bayesian design criteria: Computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model, Journal of Pharmacokinetics and Biopharmaceutics, vol.19, issue.1, pp.101-125, 1995. ,
DOI : 10.1007/BF03036255
Prediction of Shrinkage of Individual Parameters Using the Bayesian Information Matrix in Non-Linear Mixed Effect Models with Evaluation in Pharmacokinetics, Pharmaceutical Research, vol.78, issue.1???2, pp.2355-2367, 2013. ,
DOI : 10.1016/S0378-3758(98)00221-3
URL : https://hal.archives-ouvertes.fr/inserm-00849820
Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solution, American Association of Pharmaceutical Scientists Journal, vol.11, pp.558-569, 2009. ,
Current Use and Developments Needed for Optimal Design in Pharmacometrics: A Study Performed Among DDMoRe???s European Federation of Pharmaceutical Industries and Associations Members, CPT: Pharmacometrics & Systems Pharmacology, vol.2, issue.6, p.46, 2013. ,
DOI : 10.1007/s11095-011-0659-3
Robust Population Pharmacokinetic Experiment Design, Journal of Pharmacokinetics and Pharmacodynamics, vol.99, issue.1, pp.33-64 ,
DOI : 10.3181/00379727-168-41240
Comparison of Robust Criteria for D-Optimal Designs, Journal of Biopharmaceutical Statistics, vol.253, issue.1, pp.1193-1205, 2012. ,
DOI : 10.1023/A:1025701327672
Adaptive Design Theory and Implementation Using SAS and R. Boca Raton: Chapman and Hall/CRC, 2007. ,
Adaptive Optimal Design for Bridging Studies with an Application to Population Pharmacokinetic Studies, Pharmaceutical Research, vol.34, issue.6, pp.1530-1543, 2012. ,
DOI : 10.1007/s10928-007-9066-0
Influence of the Size of Cohorts in Adaptive Design for Nonlinear Mixed Effects Models: An Evaluation by Simulation for a Pharmacokinetic and Pharmacodynamic Model for a Biomarker in Oncology, Pharmaceutical Research, vol.11, issue.6, pp.3159-3169, 2015. ,
DOI : 10.1002/pst.1542
URL : https://hal.archives-ouvertes.fr/inserm-01179444
Two-stage Adaptive Designs in Nonlinear Mixed Effects Models: Application to Pharmacokinetics in??Children, Communications in Statistics - Simulation and Computation, vol.2, issue.5, pp.1511-1525, 2016. ,
DOI : 10.1038/clpt.2010.9
URL : https://hal.archives-ouvertes.fr/inserm-01076940
Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs, Computer Methods and Programs in Biomedicine, vol.65, issue.2, pp.141-151, 2001. ,
DOI : 10.1016/S0169-2607(00)00117-6
Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0, Computer Methods and Programs in Biomedicine, vol.98, issue.1, pp.55-65, 2010. ,
DOI : 10.1016/j.cmpb.2009.09.012
URL : https://hal.archives-ouvertes.fr/inserm-00431457
New features for population design evaluation and optimisation with R functions ,
Design in nonlinear mixed effects models: Optimization using the Fedorov???Wynn algorithm and power of the Wald test for binary covariates, Statistics in Medicine, vol.39, issue.28, pp.5162-5179, 2007. ,
DOI : 10.1007/978-1-4419-0318-1
URL : https://hal.archives-ouvertes.fr/hal-00263513
A Simplex Method for Function Minimization, The Computer Journal, vol.7, issue.4, pp.308-313, 1965. ,
DOI : 10.1093/comjnl/7.4.308
Theory of Optimal Experiments, 1972. ,
Results in the theory and construction of D-optimum designs, Journal of the Royal Statistical Society B, vol.34, pp.133-147, 1972. ,
Matrix Differential Calculus with Applications in Statistics and Econometrics., Biometrics, vol.44, issue.4, 1988. ,
DOI : 10.2307/2531754
A new method for evaluation of the Fisher information matrix for discrete mixed effect models using Monte Carlo sampling and adaptive Gaussian quadrature, Computational Statistics & Data Analysis, vol.111, pp.203-219, 2016. ,
DOI : 10.1016/j.csda.2016.10.011
URL : https://hal.archives-ouvertes.fr/inserm-01397584
An MCMC method for the evaluation of the Fisher information matrix for non-linear mixed effect models, Biostatistics, vol.42, issue.4, pp.737-750, 2016. ,
DOI : 10.1081/BIP-120019267
URL : https://hal.archives-ouvertes.fr/hal-01323747
Impact of modelling intra-subject variability on tests based on non-linear mixed-effects models in cross-over pharmacokinetic trials with application to the interaction of tenofovir on atazanavir in HIV patients, Statistics in Medicine, vol.13, issue.6, pp.1268-1284, 2007. ,
DOI : 10.1097/00126334-200008010-00008
URL : https://hal.archives-ouvertes.fr/inserm-00157143
A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailability, Journal of Pharmacokinetics and Biopharmaceutics, vol.12, issue.6, pp.657-680, 1987. ,
DOI : 10.1007/BF01059558
Bayesian Estimation and Experimental Design in Linear Regression Models, 1991. ,
Bayesian Experimental Design: A Review, Statistical Science, vol.10, issue.3, pp.273-304, 1995. ,
DOI : 10.1214/ss/1177009939
Numerical Recipes: The Art of Scientific Computing, 2007. ,
Mathematical expressions of the pharmacokinetic and pharmacodynamic models implemented in the MONOLIX. MONOLIX software, 2008. ,
Performance Comparison of Various Maximum Likelihood Nonlinear Mixed-Effects Estimation Methods for Dose???Response Models, The AAPS Journal, vol.14, issue.3 ,
DOI : 10.1208/s12248-012-9349-2
URL : https://hal.archives-ouvertes.fr/inserm-00709829
Evaluation of the Fisher information matrix in nonlinear mixed effect models using adaptive Gaussian quadrature, Computational Statistics & Data Analysis, vol.80, pp.57-69, 2014. ,
DOI : 10.1016/j.csda.2014.06.011
URL : https://hal.archives-ouvertes.fr/inserm-01077176
Robust design in model based analysis of longitudinal clinical data. Presented at PODE meeting, 2016. ,
Using Hamiltonian Monte Carlo to design longitudinal studies with discrete data. 154th ICB Seminar -Eleventh International Seminar on Statistics and Clinical Practice, 2017. ,
Influence of Covariance Between Random Effects in Design for Nonlinear Mixed-Effect Models with an Illustration in Pediatric Pharmacokinetics, Journal of Biopharmaceutical Statistics, vol.7, issue.4, pp.471-492, 2013. ,
DOI : 10.2165/00003088-200847040-00002
URL : https://hal.archives-ouvertes.fr/inserm-00769812
Design Optimization in Nonlinear Mixed Effects Models Using Cost Functions: Application to a Joint Model of Infliximab and Methotrexate Pharmacokinetics, Communications in Statistics - Theory and Methods, vol.34, issue.18, pp.3351-3368, 2009. ,
DOI : 10.1177/0962280206079018
URL : https://hal.archives-ouvertes.fr/inserm-00424247
Individual Bayesian Information Matrix for Predicting Estimation Error and Shrinkage of Individual Parameters Accounting for Data Below the Limit of Quantification, Pharmaceutical Research, vol.15, issue.10, p.2119, 2017. ,
DOI : 10.1002/pst.1731
URL : https://hal.archives-ouvertes.fr/inserm-01549693
Monotonic convergence of a general algorithm for computing optimal designs, The Annals of Statistics, vol.38, issue.3, pp.1593-1606, 2010. ,
DOI : 10.1214/09-AOS761
Minimax optimal designs via particle swarm optimization methods, Statistics and Computing, vol.20, issue.4, pp.975-988, 2015. ,
DOI : 10.1002/1097-0258(20010115)20:1<123::AID-SIM643>3.0.CO;2-5
URL : https://cloudfront.escholarship.org/dist/prd/content/qt9vw0p4pn/qt9vw0p4pn.pdf
Model Description Language (MDL): A Standard for Modeling and Simulation, CPT: Pharmacometrics & Systems Pharmacology, vol.1, issue.6, pp.647-650, 2017. ,
DOI : 10.1049/sb:20045008